These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38859842)

  • 1. TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer.
    Ahmed J; Nishizaki D; Miyashita H; Lee S; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S; Kurzrock R
    Am J Cancer Res; 2024; 14(5):2493-2506. PubMed ID: 38859842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome.
    Krishnamurthy N; Nishizaki D; Lippman SM; Miyashita H; Nesline MK; Pabla S; Conroy JM; DePietro P; Kato S; Kurzrock R
    Ther Adv Med Oncol; 2024; 16():17588359231220510. PubMed ID: 38188465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes.
    Adashek JJ; Kato S; Nishizaki D; Pabla S; Nesline MK; Previs RA; Conroy JM; DePietro P; Kurzrock R
    Am J Cancer Res; 2024; 14(1):368-377. PubMed ID: 38323282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer.
    Shreenivas A; Nishizaki D; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Kato S; Kurzrock R
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.
    Lim J; Kurzrock R; Nishizaki D; Miyashita H; Adashek JJ; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Lippman SM; Kato S
    Cancer Med; 2024 Jan; 13(1):e6844. PubMed ID: 38132831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
    Kato S; Okamura R; Kumaki Y; Ikeda S; Nikanjam M; Eskander R; Goodman A; Lee S; Glenn ST; Dressman D; Papanicolau-Sengos A; Lenzo FL; Morrison C; Kurzrock R
    Oncoimmunology; 2020; 9(1):1708065. PubMed ID: 32117584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics.
    Adashek JJ; Kato S; Nishizaki D; Miyashita H; De P; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Lippman S; Kurzrock R
    Cancer Med; 2023 Jun; 12(12):13155-13166. PubMed ID: 37132280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
    JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.
    Mimura K; Kua LF; Xiao JF; Asuncion BR; Nakayama Y; Syn N; Fazreen Z; Soong R; Kono K; Yong WP
    Gastric Cancer; 2021 May; 24(3):611-623. PubMed ID: 33611641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.
    Kozłowski M; Borzyszkowska D; Cymbaluk-Płoska A
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion.
    Bruss C; Kellner K; Albert V; Hutchinson JA; Seitz S; Ortmann O; Brockhoff G; Wege AK
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
    Byun KD; Hwang HJ; Park KJ; Kim MC; Cho SH; Ju MH; Lee JH; Jeong JS
    J Breast Cancer; 2018 Dec; 21(4):406-414. PubMed ID: 30607162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIM-3 expression in breast cancer.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Oncoimmunology; 2018; 7(11):e1502128. PubMed ID: 30377566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.
    Vlachostergios PJ
    Am J Transl Res; 2021; 13(11):12386-12394. PubMed ID: 34956460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance.
    Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
    J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types.
    Miyashita H; Bevins NJ; Thangathurai K; Lee S; Pabla S; Nesline MK; Glenn ST; Conroy JM; DePietro P; Rubin E; Sicklick JK; Kato S; Kurzrock R
    Am J Cancer Res; 2024; 14(5):2240-2252. PubMed ID: 38859855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer.
    Dong X; Dai H; Lin Y; Sheng X; Li Y; Wang Y; Zhang X; Jiang S; Yin W; Lu J
    J Transl Med; 2023 Jun; 21(1):400. PubMed ID: 37340461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.